Pharmacokinetics of amoxicillin in obese and nonobese subjects
© 2021 British Pharmacological Society..
AIMS: To compare the pharmacokinetics of amoxicillin (AMX) in obese and nonobese subjects, given as single dose 875-mg tablets.
METHODS: A prospective, single-centre, open-label, clinical study was carried out involving 10 nonobese and 20 obese subjects given a dose of an AMX 875-mg tablet. Serial blood samples were collected between 0 and 8 hours after administration of AMX and plasma levels were quantified by liquid chromatography-tandem mass spectrometry. The pharmacokinetic parameters (PK) were calculated by noncompartmental analysis and means of the 2 groups were compared using Student t-test. Analysis of correlation between covariates and PK was performed using Pearson's correlation coefficient.
RESULTS: Ten nonobese subjects (mean age 30.6 ± 7.12 y; body mass index 21.56 ± 1.95 kg/m2 ) and 20 obese subjects (mean age 34.47 ± 7.03 y; body mass index 33.17 ± 2.38 kg/m2 ) participated in the study. Both maximum concentration (Cmax ; 12.12 ± 4.06 vs. 9.66 ± 2.93 mg/L) and area under the curve (AUC)0-inf (34.18 ± 12.94 mg.h/L vs. 26.88 ± 9.24 mg.h/L) were slightly higher in nonobese than in obese subjects, respectively, but differences were not significant. The volume of distribution (V/F) parameter was statistically significantly higher in obese compared to nonobese patients (44.20 ± 17.85 L vs. 27.57 ± 12.96 L). Statistically significant correlations were observed for several weight metrics vs. AUC, Cmax , V/F and clearance, and for creatinine clearance vs. AUC, Cmax and clearance.
CONCLUSION: In obese subjects, the main altered PK was V/F as a consequence of greater body weight. This may result in antibiotic treatment failure if standard therapeutic regimens are administered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 87(2021), 8 vom: 30. Aug., Seite 3227-3233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soares, Ana Luiza P P D P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
804826J2HU |
|---|
| Anmerkungen: |
Date Completed 27.10.2021 Date Revised 27.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.14739 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320371212 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320371212 | ||
| 003 | DE-627 | ||
| 005 | 20231225173429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14739 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320371212 | ||
| 035 | |a (NLM)33474776 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soares, Ana Luiza P P D P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics of amoxicillin in obese and nonobese subjects |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2021 | ||
| 500 | |a Date Revised 27.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 British Pharmacological Society. | ||
| 520 | |a AIMS: To compare the pharmacokinetics of amoxicillin (AMX) in obese and nonobese subjects, given as single dose 875-mg tablets | ||
| 520 | |a METHODS: A prospective, single-centre, open-label, clinical study was carried out involving 10 nonobese and 20 obese subjects given a dose of an AMX 875-mg tablet. Serial blood samples were collected between 0 and 8 hours after administration of AMX and plasma levels were quantified by liquid chromatography-tandem mass spectrometry. The pharmacokinetic parameters (PK) were calculated by noncompartmental analysis and means of the 2 groups were compared using Student t-test. Analysis of correlation between covariates and PK was performed using Pearson's correlation coefficient | ||
| 520 | |a RESULTS: Ten nonobese subjects (mean age 30.6 ± 7.12 y; body mass index 21.56 ± 1.95 kg/m2 ) and 20 obese subjects (mean age 34.47 ± 7.03 y; body mass index 33.17 ± 2.38 kg/m2 ) participated in the study. Both maximum concentration (Cmax ; 12.12 ± 4.06 vs. 9.66 ± 2.93 mg/L) and area under the curve (AUC)0-inf (34.18 ± 12.94 mg.h/L vs. 26.88 ± 9.24 mg.h/L) were slightly higher in nonobese than in obese subjects, respectively, but differences were not significant. The volume of distribution (V/F) parameter was statistically significantly higher in obese compared to nonobese patients (44.20 ± 17.85 L vs. 27.57 ± 12.96 L). Statistically significant correlations were observed for several weight metrics vs. AUC, Cmax , V/F and clearance, and for creatinine clearance vs. AUC, Cmax and clearance | ||
| 520 | |a CONCLUSION: In obese subjects, the main altered PK was V/F as a consequence of greater body weight. This may result in antibiotic treatment failure if standard therapeutic regimens are administered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a amoxicillin | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 700 | 1 | |a Montanha, Maiara C |e verfasserin |4 aut | |
| 700 | 1 | |a Alcantara, Conrado D S |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Sandra R B |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroda, Cristina M |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Sérgio S |e verfasserin |4 aut | |
| 700 | 1 | |a Nicacio, Antônio E |e verfasserin |4 aut | |
| 700 | 1 | |a Maldaner, Liane |e verfasserin |4 aut | |
| 700 | 1 | |a Visentainer, Jesui V |e verfasserin |4 aut | |
| 700 | 1 | |a Simões, Caroline F |e verfasserin |4 aut | |
| 700 | 1 | |a Locatelli, João Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Wendell A |e verfasserin |4 aut | |
| 700 | 1 | |a Mazucheli, Josmar |e verfasserin |4 aut | |
| 700 | 1 | |a Diniz, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Paixão, Paulo J P A |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Elza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 87(2021), 8 vom: 30. Aug., Seite 3227-3233 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g number:8 |g day:30 |g month:08 |g pages:3227-3233 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14739 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2021 |e 8 |b 30 |c 08 |h 3227-3233 | ||